Science
Sunnybrook study links menopause blood markers to later cognitive aging risk
Nature Medicine research finds post-menopausal molecular shifts detectable in blood and associated with memory decline and Alzheimer’s risk years later — not a personal prediction tool yet.
Published: October 2, 2026 · Updated: October 2, 2026 · 1 min read
Across nearly 12,000 older post-menopausal women in four cohorts, higher menopause-related blood proteins were linked to steeper later declines in memory and thinking and greater Alzheimer’s dementia risk. Co-author Dr. Kaitlin Casaletto of UCSF said the work helps explain differences in women’s brain aging after menopause; Rabin stressed menopause is not a diagnosis of dementia and that the signals cannot yet predict any individual’s risk. The collaboration spanned Sunnybrook, U of T, UCSF, the U.S. National Institute on Aging and several U.S. universities. This article is for general information only and is not a substitute for professional medical advice. Consult a clinician about personal health concerns. Sources: Sunnybrook Research Institute.
Sources
- Sunnybrook Research Institute · other
Newsletter
News. Context. What matters.
One essential briefing, written for people who would rather understand the story than scroll it.
Unsubscribe anytime. We don’t sell addresses.
Recommended
Science
UBC maps B.C. teen's H5N1 mutations and finds they weakened human-cell binding
Cryo-electron microscopy of Canada's first locally acquired human bird-flu case shows two surface-protein changes reduced receptor latching, challenging early fears the virus was adapting toward people.
Science
New Brunswick will offer free RSV shots to all newborns starting Oct. 13
The province is spending $3.8 million so babies under two can get immunization against respiratory syncytial virus without the hundreds-of-dollars out-of-pocket cost.
Science
Canadian CALM trial maps why youth often face multiple mental-health diagnoses together
A BMC Psychiatry protocol details a six-site master observational study of multimorbidity in ages 11–24, with deep phenotyping and room for embedded trials.